Lidocaine transdermal patch - Scilex Pharmaceuticals

Drug Profile

Lidocaine transdermal patch - Scilex Pharmaceuticals

Alternative Names: Lidocaine 1.8% patch - Scilex Pharmaceuticals; Ztilido™; ZTlido

Latest Information Update: 13 Jan 2017

Price : $50

At a glance

  • Originator Scilex Pharmaceuticals
  • Class Acetanilides; Class Ib antiarrhythmics; Local anaesthetics; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Postherpetic neuralgia

Most Recent Events

  • 09 Jan 2017 SCILEX Pharmaceuticals intends to submit as part of a hybrid MAA to MHRA in United Kingdom
  • 05 Dec 2016 Initial pharmacokinetics data from a bioequivalence clinical trial in Postherpetic neuralgia released by Scilex Pharmaceuticals
  • 11 Nov 2016 Scilex Pharmaceuticals plans to re-submit the NDA for lidocaine transdermal patch (1.8%)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top